Nautilus Biotechnology (NAUT) Cash from Operations Growth (3y) (2023 - 2026)
Nautilus Biotechnology (NAUT) Cash from Operations Growth (3y) (2023 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,042.03 Bn | 67,041.74 Bn | - | -5.07% |
| 2 | Nanobiotix | 1,908.00 Bn | 1,907.94 Bn | - | - |
| 3 | Akari Therapeutics | 959.56 Bn | 959.56 Bn | - | - |
| 4 | BeOne Medicines | 471.84 Bn | 467.05 Bn | 1.35 Bn | 33.08% |
| 5 | Vertex Pharmaceuticals | 122.13 Bn | 114.88 Bn | 2.59 Bn | 16.64% |
| 6 | Regeneron Pharmaceuticals | 70.01 Bn | 61.26 Bn | 3.31 Bn | -7.60% |
| 7 | Belite Bio | 62.34 Bn | 62.34 Bn | - | - |
| 8 | Argenx Se | 55.93 Bn | 50.74 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.49 Bn | 34.48 Bn | 959.66 Mn | 34.32% |
| 10 | Nautilus Biotechnology | 212.75 Mn | 116.88 Mn | - | -1.51% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.51% |
| Dec 31, 2025 | -6.05% |
| Sep 30, 2025 | -4.88% |
| Jun 30, 2025 | 0.44% |
| Mar 31, 2025 | -4.15% |
| Dec 31, 2024 | -10.80% |
| Sep 30, 2024 | 2.57% |
| Jun 30, 2024 | -23.07% |
| Mar 31, 2024 | -37.53% |
| Dec 31, 2023 | -193.54% |
| Sep 30, 2023 | -189.13% |